Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom?

In the e-first version of the above-mentioned article one sentence is incorrect (first paragraph of the section “Abemaciclib”). Correct is: Randomization had to occur within 16 months after surgery. Furthermore, the last paragraph of the section should read correctly: Abemaciclib has been approved in Germany for patients with HR+/HER2− eBC and more than three involved lymph nodes or with 1–3 involved lymph nodes and a tumor size of more than 5 cm (T3 stage) or a poorly differentiated tumor (G3) [7]. This was corrected in the online version on 22.5.2025.